Simvastatin Alleviates ConA-Induced Autoimmune Hepatitis by Inhibiting CD4⁺ T Cell Activation via Calcium-NFATC3...

Area of Science:

• Immunology
• Hepatology
• Pharmacology

Background:

• Autoimmune hepatitis (AIH) involves immune-mediated liver damage.
• Simvastatin is a statin drug with known roles in lipid management and other conditions.
• The effects of simvastatin on AIH are not well understood.

Purpose of the Study:

• To investigate the therapeutic potential of simvastatin in a mouse model of autoimmune hepatitis (AIH).
• To elucidate the underlying mechanisms by which simvastatin affects T cells in AIH.

Main Methods:

• Concanavalin A (ConA)-induced AIH mouse model.
• Simvastatin treatment and assessment of liver injury markers (ALT, AST).
• Flow cytometry for T cell apoptosis and cytokine secretion.
• Transcriptome sequencing (RNA-seq) of CD4+ T cells.
• Quantitative PCR (qPCR) and flow cytometry for pathway analysis.

Main Results:

• Simvastatin treatment alleviated liver injury, reducing ALT and AST levels.
• Simvastatin promoted CD4+ T cell apoptosis and decreased inflammatory cytokines (IL-17A, IL-6, IFN-γ, TNF-α).
• RNA-seq identified the calcium signaling pathway and NFATC3 as key targets.
• Simvastatin suppressed the calcium signaling pathway and NFATC3 expression in CD4+ T cells.

Conclusions:

• Simvastatin demonstrates therapeutic efficacy in experimental AIH.
• Simvastatin alleviates AIH by modulating CD4+ T cell responses.
• The drug's mechanism involves suppressing the calcium-dependent signaling pathway and NFATC3.